Loading...
Guest User
Welcome! Please login.
* - Tentative Dates
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Fund Subsidiary for purchasing new plant and machinery at its new production facility. | 6.85 |
| 2 | To Meeting the working capital requirements of the Company. | 5.00 |
| 3 | General Corporate Purposes | 3.17 |
| Total | 15.02 |
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 58.65 | 25.16 | 16.71 |
| Total Income | 33.42 | 29.48 | 24.67 |
| Profit After Tax | 2.01 | 0.23 | 2.04 |
| Reserves and Surplus | 12.02 | 9.89 | 0.11 |
| Amount in ₹ Crore | |||
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Fees ofthe Bankers to the Issue, Registrar to the Issue, Legal Advisor, Auditor’s fees, Monitoring Agency, including out of pocket expenses etc. | 0.17 |
| 2 | Expenses relating to advertising, printing, distribution, marketing and stationery expenses | 0.02 |
| 3 | Regulatory fees, filing fees, listing fees Stamp Duty and other miscellaneous expenses | 0.06 |
| Total | 0.25 |
Sunrest Lifescience Limited provides an extensive range of healthcare and personal care products. Its offerings include capsules, tablets, syrups, ointments, gels, mouthwashes, solutions, suspensions, dry powders, and toothpaste. The company’s product portfolio spans multiple therapeutic categories such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, dental care, antiprotozoal, antihistamine, antihypertensive, cosmetic, antiparasitic, anti-inflammatory, as well as multivitamins, multiminerals, and nutraceuticals.
Sunrest operates through a third-party manufacturing model, partnering with 43 pharmaceutical manufacturers across states like Gujarat, Punjab, Maharashtra, Haryana, Himachal Pradesh, Uttarakhand, and Madhya Pradesh. Among these partners is Trilend Pharmaceuticals, a group company of Sunrest.
